The Effects of Tirzepatide in People With Overweight/Obesity and Coronary Artery Disease
NCT06606821 on ClinicalTrials.gov · last registry update 2025-05-22
Recruiting now, toward 124 participants. Due to report 20 March 2027, alongside 30 other tracked readouts that quarter. Primary outcome, as filed: Lipid core burden index. Sponsors move these dates routinely; any movement since this site started watching is listed below. tirzepatide is already approved in the US for cardiovascular disease and obesity, so this is asking a further question rather than establishing the drug works at all.
- Status
- RECRUITING
- Phase
- P4
- Drug
- tirzepatideZepbound, Mounjaro
- Sponsor
- Tina Vilsbøll
- Sponsor type
- Other
- Enrollment
- 124
- Started
- 2024-10-01
- Primary completion
- 2027-03-20 estimated
Observed history
No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.
Primary outcome
Lipid core burden index
Conditions studied
Coronary Artery Disease · Coronary Microvascular Dysfunction · Overweight or Obesity · Stable Angina Pectoris · Chronic Coronary Artery Disease · Atherosclerosis Cardiovascular Disease
Every field above is taken directly from the registry record. See all detected changes across the class, or the tirzepatide page for this molecule’s full trial and approval history.